Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Disease
- Antibody
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 261587
License Grant
The License grants the Canadian Licensee a non-exclusive right to certain of the Irish Licensors patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems.
License Property
These patents and related know-how cover some key aspects of our product Vicinium for bladder cancer treatment. Recombinant protein expression technology enables analysis of gene regulation and protein structure and function.
Field of Use
This agreement pertains to the cancer drug industry.
IPSCIO Record ID: 304180
License Grant
Licensor grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products to the Licensee.
License Property
These patents cover some key aspects of Vicinium.
Vicinium, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC).
Field of Use
The agreement grants Licensee access to Licensor’s patent technology for certain antibody products to be used for the treatment of bladder cancer.
Licensee is a late-stage clinical company developing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer.
IPSCIO Record ID: 121012
License Grant
Pursuant to this Settlement and Cross-license agreement, Licensor grants to Licensee of Bermuda under all Licensor Patents, on a country-by-country basis in the Licensees Territory, an exclusive, sublicenseable license to make, have made, use, sell, have sold and import Licensees Licensed Products for the treatment, prophylaxis or diagnosis of any disease or condition in humans; with respect to Licensees Licensed Products containing an Anti-IgE Antibody identified and synthesized before June 1, 1997, and/or Licensors Patents issued before June 1, 1999.
License Property
Anti-IgE Antibody means an antibody directed against the immunoglobulin IgE as an antigen, fragments or conjugates of such antibodies, and other constructs comprising antibodies which are derived from or contain any of the above-specified components.
Licensees Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody.
Licensors Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody identified and synthesized by Licensor and/or a third party, or other IgE inhibiting antibodies within Licensorss MIGIS(R) program.
Field of Use
The agreement is for the drug industry relating to antibodies for immunology, infectious diseases and cancer.
IPSCIO Record ID: 202855
License Grant
Licensor grants to Licensee under all Licensors Patents a nonexclusive, worldwide, sublicensable license to the extent necessary to make, have made, use, sell, have sold and import Licensees Licensed Products for the treatment, prophylaxis or diagnosis of any disease or condition in humans and animals; provided, however, that with respect to Licensees Licensed Products containing an Anti-IgE Antibody identified and synthesized before June 1, 1997, and/or Licensors Patents issued before June 1, 1999, the foregoing limitation -to the extent necessary- shall not be applicable.
License Property
Anti-IgE Antibody means an antibody directed against the immunoglobulin IgE as an antigen, fragments or conjugates of such antibodies, and other constructs comprising antibodies which are derived from or contain any of the above-specified components.
Licensees Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody.
Licensors Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody identified and synthesized by Licensor and/or a third party, or other IgE inhibiting antibodies within Licensorss MIGIS(R) program.
Field of Use
The agreement is for antibodies for immunology, infectious diseases and cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
